AdPEDF gene therapy

Drug Profile

AdPEDF gene therapy

Alternative Names: Ad35 adenovector delivery; Ad35PEDF; AdGVPEDF.11D; AdPEDF; AdPEDF.11D; Blindness prevention programme - GenVac; PEDF gene therapy; Pigment epithelium-derived factor gene therapy - GenVec

Latest Information Update: 29 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator National Institutes of Health (USA); Northwestern University
  • Developer GenVec
  • Class Eye disorder therapies; Gene therapies
  • Mechanism of Action Angiogenesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Age-related macular degeneration; Diabetic retinopathy

Most Recent Events

  • 16 Jun 2017 GenVec was acquired by Intrexon Corporation
  • 21 May 2008 GenVec receives grant from National Eye Institute for AdPEDF gene therapy development in wet AMD
  • 29 Feb 2008 Phase I evaluation is ongoing for Age-related macular degeneration
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top